SCHEMBL8214008

SCHEMBL8214008

CN[C@H]1CC[C@@H](N(C)C)CC1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 19/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6142299 1.00 IRAK4 (0.34) IRAK4
SCHEMBL14724552 1.00 IRAK4 (0.34) IRAK4
SCHEMBL10109671 0.93 IRAK4 (0.32) IRAK4
SCHEMBL19723229 0.84
SCHEMBL17488360 0.84
SCHEMBL17488359 0.84
SCHEMBL530404 0.78 KDM1A (0.38)
SCHEMBL665282 0.78 KDM1A (0.38)
SCHEMBL17458 0.78
SCHEMBL11525280 0.78 KDM1A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 US disclosed
WO-2021262596-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 WO disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 US disclosed
EP-2917195-B9 SPLICEOSTATIN ANALOGS PFIZER (US) 2018-05-30 EP disclosed
US-9764040-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2017-09-19 US disclosed
US-20170014523-A1 SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION PFIZER (US) 2017-01-19 US disclosed
US-9504669-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2016-11-29 US disclosed
US-20160022626-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION PFIZER (US) 2016-01-28 US disclosed
US-9169264-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2015-10-27 US disclosed
US-20140134193-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION PFIZER INC. (US) 2014-05-15 US disclosed
WO-2014068443-A1 SPLICEOSTATIN ANALOGS PFIZER INC. (US) 2014-05-08 WO disclosed
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE GRAUERT MATTHIAS 2009-04-09 US disclosed
WO-2008065500-A2 HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2008-06-05 WO disclosed
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022626-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION SF3B5, SNRPA1, SF3B1 IRAK4 2245/4885
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS IRAK4 4046/4885
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound REN, NR3C2, NR5A1 IRAK4 3920/4885
US-20140134193-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION SF3B5, SNRPA1, SF3B1 IRAK4 2245/4885
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE CYP3A43, CYP3A5, UGT1A3 IRAK4 2231/4885
US-20170014523-A1 SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION SF3B5, SF3B1, SNRPA1 IRAK4 1503/4885
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE CYP3A43, CYP3A5, UGT1A3 IRAK4 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.